Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment
Shuqin Chen,Xuepeng Wang,Yong Jin,Xueqin Chen,Qifa Song,Gang Wei,Li Li
DOI: https://doi.org/10.2147/dmso.s443631
2024-03-13
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Shuqin Chen, 1, &ast Xuepeng Wang, 2, &ast Yong Jin, 3 Xueqin Chen, 4 Qifa Song, 5 Gang Wei, 6 Li Li 1 1 Department of Endocrinology and Metabolism, The First Affiliated Hospital of Ningbo University, Ningbo, People's Republic of China; 2 Department of Infectious Disease, The First Affiliated Hospital of Ningbo University, Ningbo, People's Republic of China; 3 Department of Internal Medicine, Ningbo Yinzhou No.2 Hospital, Ningbo, People's Republic of China; 4 Department of Traditional Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, People's Republic of China; 5 Medical Data Center, The First Affiliated Hospital of Ningbo University, Ningbo, People's Republic of China; 6 Beijing Diabetes Institute, Beijing Key Laboratory of Diabetes Research and Care, Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Li Li, Department of Endocrinology and Metabolism, The First Affiliated Hospital of Ningbo University, Ningbo, 31500, People's Republic of China, Email Gang Wei, Beijing Diabetes Institute, Beijing Key Laboratory of Diabetes Research and Care, Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100000, People's Republic of China, Email Background: Changes in body composition accompanied by glucagon-like peptide 1 receptor agonist (GLP-1RA) induced weight loss have drawn much attention. However, fewer studies have reported body composition changes in patients receiving dulaglutide therapy in Chinese population. Methods: A total of 70 overweight/obese type 2 diabetes mellitus (T2DM) patients who received dulaglutide therapy were included. Clinical data were collected. Visceral fat area (VFA) and body composition were also measured. Changes in clinical indicators and body composition of patients before and after intervention were also analyzed. Correlation analysis and multiple linear regression model were used to evaluate the association between hemoglobin A1C (HbA1c) and body composition. Results: The results showed that body weight (BW), VFA, body fat (BF), lean body mass (LBM), skeletal muscle mass (SMM) and water content were reduced after 3 months dulaglutide intervention. The lean body mass percentage (LBMP) and skeletal muscle mass percentage (SMMP) significantly increased. Moreover, there was no significant difference in bone mineral quality (BMQ) after the intervention. The multiple linear regression model revealed that the % change in BF was independently associated with % change in HbA1c (β = 0.449, t = 3.148, p=0.002). Conclusion: These results indicate that dulaglutide intervention does not cause muscle and bone mass loss while inducing weight loss, and % change in BF was independently associated with improved glucose control during dulaglutide therapy. This study offers some positive results to support the clinical application of dulaglutide. Keywords: dulaglutide, obesity, diabetes, body fat mass, visceral fat T2DM is a chronic metabolic disease that causes significant economic and social burdens worldwide. 1 Traditional hypoglycemic agents, such as sulfonylureas and insulin, cannot play effective hypoglycemic roles when used in patients with severe insulin resistance, and can cause side effects, as patients may gain weight after therapy. Increasing the drug dosage to enhance hypoglycemic effects may increase the risk of hypoglycemia. Therefore, identifying new drug targets and more effective and safer therapies are urgently needed. Glucagon-like peptide-1 (GLP-1), which is secreted by intestinal enteroendocrine L cells, exerts antidiabetic effects by activating GLP-1 receptors. During food intake, GLP-1 stimulates insulin secretion and inhibits glucagon secretion to lower serum glucose levels. 2 In addition, GLP-1 can improve pancreatic β-cell function and inhibit β-cell apoptosis, which can prevent or slow the progression of β cell failure in T2DM. 3,4 When glucose levels are normal, the insulinotropic effect of GLP-1 is minimal and the risk of hypoglycemia is relatively low. 5 GLP-1 can also delay the emptying of the gastrointestinal tract, increase satiety, and reduce food intake, all of which contribute to weight loss. 6–8 Because of their potent antidiabetic effects, GLP-1RAs have emerged as novel hypoglycemic agents with excellent weight loss effects and a low risk of hypoglycemia. Dulaglutide, a typical long-acting GLP-1 RA, can significantly prolong the effect time by changing its molecular s -Abstract Truncated-
endocrinology & metabolism